10-Q: Global Medical REIT Reports Q3 Loss, Extends Debt Maturities

Global Medical REIT Inc. reported a net loss for Q3 2025, driven by an impairment charge and increased interest expenses, while successfully extending significant debt maturities post-quarter.

Summary

• Reported a net loss of $5.1 million for the three months ended September 30, 2025, a significant decline from net income of $3.4 million in the prior year period.
• Reported a net loss of $0.7 million for the nine months ended September 30, 2025, compared to net income of $3.8 million for the same period in 2024.
• Rental revenue increased to $37.0 million in Q3 2025 from $34.2 million in Q3 2024, and to $109.5 million for the nine months from $103.5 million.
• Interest expense rose to $8.2 million in Q3 2025 from $7.2 million in Q3 2024, and to $23.4 million for the nine months from $21.1 million.
• Recognized a $6.3 million impairment loss on an investment property in Aurora, Illinois during Q3 2025.
• Completed a one-for-five reverse stock split on September 19, 2025, reducing authorized shares from 500 million to 100 million.
• The quarterly common stock dividend was reduced from $1.05 to $0.75 per share, effective May 28, 2025.
• Acquired a five-property portfolio for $69.6 million and disposed of five properties for $13.4 million gross proceeds during the nine months ended September 30, 2025.
• Post-quarter, the Credit Facility was amended and restated on October 8, 2025, extending the Revolver maturity to October 2029 and Term Loan A tranches to October 2029, 2030, and April 2031.
• Entered into $350 million of new forward-starting interest rate swaps on October 7, 2025, to hedge Term Loan A tranches from May 2026 at fixed SOFR rates between 3.24% and 3.32%.

Sentiment

Score: 4

Explanation: While the company successfully extended debt maturities and showed FFO/AFFO growth, the significant net loss, impairment charge, and dividend reduction indicate financial strain. The future outlook on interest expense and tenant risks also presents challenges, outweighing the positives of revenue growth and debt restructuring.

Positives

• Rental revenue increased to $37.0 million in Q3 2025 from $34.2 million in Q3 2024, and to $109.5 million for the nine months from $103.5 million, driven by acquisitions.
• FFO per share and unit increased to $1.00 in Q3 2025 from $0.96 in Q3 2024.
• AFFO per share and unit increased to $1.12 in Q3 2025 from $1.08 in Q3 2024.
• Successfully amended and restated the Credit Facility post-quarter, extending significant debt maturities and removing the 0.10% SOFR credit spread adjustment, improving long-term debt profile.
• Entered into new interest rate swaps to fully hedge Term Loan A tranches, providing interest rate certainty for an extended period from May 2026.
• Management believes it complied with all financial and non-financial debt covenants as of September 30, 2025.
• The Board approved a $50 million common stock repurchase program, indicating potential confidence in valuation and a commitment to shareholder returns.

Negatives

• Reported a net loss of $5.1 million for the three months ended September 30, 2025, a significant decline from net income of $3.4 million in the prior year period.
• Reported a net loss of $0.7 million for the nine months ended September 30, 2025, compared to net income of $3.8 million in the prior year period.
• Incurred a $6.3 million impairment loss on an investment property in Aurora, Illinois during Q3 2025.
• The quarterly common stock dividend was reduced from $1.05 to $0.75 per share, effective May 28, 2025.
• Interest expense increased by $1.0 million in Q3 2025 and $2.3 million for the nine months, primarily due to higher average borrowings and higher interest rates.
• The weighted average interest rate of debt increased to 4.06% at September 30, 2025, from 3.75% at December 31, 2024.
• Expected material increases in interest expense on fixed-rate indebtedness starting May 2026, as new interest rate swaps will fix SOFR at significantly higher rates (3.24% to 3.32%) compared to the expiring swaps (1.36%).
• Recognized an equity loss from an unconsolidated joint venture of $33 thousand in Q3 2025 and $123 thousand for the nine months.
• General and administrative expenses increased due to general corporate expenses and costs related to the CEO transition.

Risks

• Difficulties in identifying healthcare facilities to acquire due to increased cost of capital, competition, or other factors, and completing such acquisitions.
• Defaults on or non-renewal of leases by tenants, impacting rental revenue.
• Inability to collect rents from tenants.
• Increases in interest rates and increased operating costs, which can negatively affect profitability.
• Macroeconomic and geopolitical factors, including inflationary pressures, tariffs, international trade policies, elevated interest rates, distress in the banking sector, global supply chain disruptions, and ongoing geopolitical conflicts and war.
• Changes in current healthcare and healthcare real estate trends and costs, including wage inflation, which can impact tenant financial health.
• The impact of an epidemic or pandemic (such as COVID-19) and government measures to address it.
• Inability to satisfy covenants in existing and future debt agreements or to refinance existing debt on favorable terms.
• Decreased rental rates or increased vacancy rates in properties.
• Adverse economic or real estate conditions or developments, nationally or in specific markets.
• Failure to generate sufficient cash flows to service outstanding obligations or satisfy short and long-term liquidity requirements.
• Inability to deploy debt and equity capital effectively.
• Inability to hedge interest rate risk effectively.
• Inability to raise additional equity and debt capital on attractive terms or at all.
• Inability to make distributions on common and preferred stock or to redeem preferred stock.
• Use of joint ventures may limit returns and flexibility with jointly-owned investments.
• General volatility of the market price of common and preferred stock.
• Changes in business or investment/financing strategy.
• Dependence upon key personnel, whose continued service is not guaranteed.
• Inability to identify, hire, and retain highly qualified personnel.
• The degree and nature of competition in the healthcare real estate market.
• Changes in healthcare laws, governmental regulations, tax laws, and similar matters.
• Changes in expected trends in Medicare, Medicaid, and commercial insurance reimbursement, including mandated Medicaid cuts from the One Big Beautiful Bill Act (OBBBA).
• Competition for investment opportunities.
• Failure to successfully integrate acquired healthcare facilities.
• Changes in accounting policies generally accepted in the United States of America (GAAP).
• Lack of, or insufficient amounts of, insurance.
• Changes in the tax treatment of distributions.
• Failure to maintain qualification as a real estate investment trust (REIT) for U.S. federal income tax purposes.
• Limitations imposed on the business due to, and inability to satisfy, complex rules relating to REIT qualification for U.S. federal income tax purposes.
• Global trade disruption, significant introductions of trade barriers, and bilateral trade frictions could adversely affect performance.

Future Outlook

The company anticipates a material increase in interest expense on its fixed-rate indebtedness starting May 2026, as new interest rate swaps will fix the SOFR component at significantly higher rates (3.24% to 3.32%) compared to the expiring swaps (1.36%). This is expected to negatively affect net income. The company also notes that any future increases in the U.S. inflation rate could lead the Federal Reserve to pause or increase the Fed Funds Rate, further increasing interest expense on floating-rate debt. Broader industry trends include an aging population and a shift towards outpatient care, which are expected to positively impact operations, while healthcare wage inflation and changes in third-party reimbursement methods (like Medicaid cuts from the OBBBA) are expected to negatively impact tenant businesses and potentially their ability to pay rent.

Management Comments

• "We believe the reduction to the dividend best positions the Company for future growth, strengthens the balance sheet, and provides investors with an attractively yielding, well-covered dividend."
• "Management believed it complied with all of the financial and non-financial covenants contained in the Credit Facility."
• "We believe this strategy allows us to attain our goals of providing stockholders with (i) attractive dividends and (ii) stock price appreciation."
• "Our Board continues to lead our sustainability efforts, and our Board has a standing committee focused on such efforts."
• "We stand with our communities, tenants, and stockholders in supporting meaningful solutions that address this global challenge and contribute to the sustainability of our business objectives."

Industry Context

The healthcare real estate sector is influenced by an aging U.S. population and a continuing shift towards outpatient care, which are favorable trends for the company's portfolio of medical office buildings and decentralized facilities. However, the industry faces significant headwinds from elevated interest rates, which increase borrowing costs for REITs, and persistent healthcare wage inflation impacting tenant profitability. Additionally, changes in third-party reimbursement policies, such as the Medicaid cuts mandated by the OBBBA, pose a risk to tenant financial health and their ability to meet lease obligations. Physician practice group and hospital consolidation is seen as a positive trend, potentially strengthening tenant credit quality.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently subject to any material litigation, nor is any material litigation threatened, that would have a material adverse effect on its financial position, results of operations, or cash flows. No governmental authority is contemplating any proceeding to which the company is a party or its properties are subject.

Related Party Transactions

• Amounts due from related parties were $367 thousand as of September 30, 2025, primarily consisting of taxes paid on behalf of LTIP Unit and OP Unit holders and management fees owed by the unconsolidated Joint Venture.
• The company holds a 12.5% ownership interest in the unconsolidated joint venture, GII Global Medical Holdings LLC, which was formed in December 2024.

Stakeholder Impact

• Shareholders experienced a significant net loss and a reduction in common stock dividends, potentially impacting immediate returns. The reverse stock split adjusted share count but not ownership percentage (except for fractional shares). The stock repurchase program could offer future value.
• Employees, including directors and officers, are subject to stock-based compensation plans (LTIP Units), with new grants made in connection with the new CEO appointment.
• Tenants face challenges from continued healthcare wage inflation and changes in third-party reimbursement methods, such as Medicaid cuts from the OBBBA, which may impact their ability to pay rent.
• Creditors benefit from the successful amendment of the Credit Facility, extending maturities and demonstrating compliance with covenants, although future interest expense increases could affect debt service capacity.

Next Steps

• New forward-starting interest rate swaps will become effective in May 2026 to hedge Term Loan A tranches.
• The Compensation Committee and Board will determine the extent to which 2025 Annual Award Performance Goals were achieved and calculate earned LTIP Units in February 2026.
• Earned 2025 Annual Award LTIP Units will vest in two installments: 50% on the valuation date (expected Feb 2026) and 50% one year later.
• Long-Term Awards will vest following a three-year performance period, with 50% vesting the day prior to the third anniversary of the respective grant dates and the remaining 50% one year later.
• The company may purchase up to $50 million of its outstanding common stock under the Stock Repurchase Program.
• The company may offer and sell shares under its $300 million ATM equity offering program.

Key Dates

Recommendation

The company faces significant headwinds, including a net loss, a substantial impairment charge, and a dividend reduction, which are clear negative signals. The anticipated material increase in interest expense from new swaps starting May 2026 will further pressure profitability. While the successful extension of debt maturities and the stock repurchase program offer some stability and potential future value, the immediate financial performance and the challenging industry environment (wage inflation, reimbursement cuts) suggest a cautious 'hold' stance. Investors should monitor the impact of the new interest rate swaps and the company's ability to navigate the healthcare industry's cost pressures.

Keywords

Healthcare REIT, Medical Office Buildings, Real Estate Investment Trust, SEC 10-Q, Financial Results, Dividend Cut, Debt Refinancing, Interest Rate Swaps, Reverse Stock Split, Property Acquisitions, Property Dispositions, Impairment Loss, Corporate Governance, Risk Factors, GMRE, Healthcare Real Estate